MD Magazine (2/21, Rosenfeld) reported, “Varenicline, an effective medication for smoking cessation, was not associated with an increased risk of cardiovascular or neuropsychiatric hospitalizations compared with nicotine replacement therapy,” research indicated. In comparison, “bupropion, a smoking cessation aid and antidepressant, was linked with lower risks of cardiovascular hospitalizations and higher risks of neuropsychiatric hospitalizations compared with nicotine replacement therapy.” Included in the 618,500-patient study were 454,698 who “used varenicline,” 131,562 who “used bupropion, and 32,237” who “used nicotine replacement therapy.” The findings were published online Feb. 19 in the journal Addiction.
Related Links:
— “Varenicline Safe for Smoking Cessation, Reduces Hospitalization Risk, “Samara Rosenfeld, MD Magazine, February 21, 2020